Evaluation of the efficacy of glecaprevir and pibrentasvir for Japanese hepatitis C patients: a prospective study in real life settings.
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 Dec 2018 Planned number of patients changed from 100 to 350.
- 13 Mar 2018 New trial record